SCHEMBL30622017

SCHEMBL30622017

CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5CN(C6CCOC6)C5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1

nearest known ligand 0.91

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 20/20 0.91
▸ BCL2L1 Q07817 2/20 0.81
▸ NSD2 O96028 1/20 0.81
▸ ADORA3 P0DMS8 1/20 0.81
▸ CYP2C9 P11712 1/20 0.81
▸ ADRA2C P18825 1/20 0.81
▸ SLC6A2 P23975 1/20 0.81
▸ BID P55957 1/20 0.81
▸ SLC6A3 Q01959 1/20 0.81
▸ MCL1 Q07820 1/20 0.81
▸ ASPH Q12797 1/20 0.81
▸ BCL2L2 Q92843 1/20 0.81
▸ BAD Q92934 1/20 0.81
▸ NSD1 Q96L73 1/20 0.81
▸ NSD3 Q9BZ95 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1699893 1.00 BCL2 (0.91) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL30314040 0.97 BCL2 (0.94) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1699868 0.97 BCL2 (0.94) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL30314054 0.97 BCL2 (0.95) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1701597 0.97 BCL2 (0.95) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1699886 0.97 BCL2 (0.95) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL31344663 0.97 BCL2 (0.95) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1699873 0.95 BCL2 (0.95) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL30314072 0.95 BCL2 (0.95) BCL2BCL2L1NSD2ADORA3CYP2C9
SCHEMBL1699856 0.95 BCL2 (0.95) BCL2BCL2L1NSD2ADORA3CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4474383-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2024-12-11 — — EP disclosed
EP-2435432-B3 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE IRELAND UNLIMITED CO (BM) 2023-10-25 — — EP disclosed
Send feedback